Date: 2016-01-26
Type of information: Milestone
Compound: anetumab ravtansine (BAY 94-9343)
Company: ImmunoGen (USA - MA) Bayer Healthcare (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: antibody drug conjugate. Anetumab ravtansine is an antibody-drug conjugate (ADC) targeting mesothelin. This ADC has been developed by Bayer using MorphoSys's HuCAL technology. Bayer is developing anetumab ravtansine under a 2008 license agreement with ImmunoGen that granted the company exclusive rights to use ImmunoGen's maytansinoid ADC technology to develop anticancer therapies targeting mesothelin. Bayer is responsible for the development, registration, and commercialization of anetumab ravtansine. ImmunoGen is entitled to receive milestone payments potentially totaling up to $170 million and royalties on commercial sales, if any.
Disease:
Details: * On January 26, 2016, ImmunoGen announced the Company earned a milestone payment with Bayer's initiation of a global Phase 2 clinical study designed to support registration of anetumab ravtansine (BAY 94-9343).
Financial terms:
Latest news:
